eXoZymes, Inc. (EXOZ)
NASDAQ: EXOZ · Real-Time Price · USD
7.40
+0.27 (3.81%)
Mar 19, 2026, 10:50 AM EDT - Market open
eXoZymes Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
31
Market Cap
62.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 70.07K | 41.47K | 145.01% |
| Dec 31, 2022 | 28.60K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionEXOZ News
- 1 day ago - Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability - Accesswire
- 6 days ago - eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium - Accesswire
- 5 weeks ago - With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation - Accesswire
- 6 weeks ago - eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run - Accesswire
- 3 months ago - eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion - Accesswire
- 4 months ago - eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today - Accesswire
- 4 months ago - eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff - Accesswire
- 4 months ago - eXoZymes to Host Third Quarter 2025 Update on Thursday November 13, 2025, at 5PM EST - Accesswire